Vaxo-Q-Re is a new advanced therapy consisting of five types of immune cells;

  • Macrophages.
  • NK cells.
  • Dendritic cells.
  • Cytotoxic T lymphocytes.
  • Antibody-producing plasma cells.

Proven in breast cancer cells, but effective in treating all forms of the disease, adoptive T cell-based therapy encourages the body's immune system to attack cancer cells.

Vaxo-Q-Re has been under development by RGCC scientists for more than five years and is now categorized as a cell therapy medicinal product (CTMP) by the European Medicines Agency (EMA).

For more information